Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 09:00PM GMT
Release Date Price: $20.81 (-1.05%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. It's my great pleasure to introduce our last but not least presenting company today, REGENXBIO. With us today, we have Steve Pakola, Chief Medical Officer.

Questions & Answers

Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Steve, so maybe I'll start with the big picture question. So how do you plan to achieve the new strategic goal of 5x25?

Stephen Pakola
REGENXBIO Inc. - Executive VP & Chief Medical Officer

Great. First, thanks, Gena, for having us. It's always great to be down in Miami and get a chance to chat and meet others. Yes, so our 5x25 plan. So this is a plan that our CEO, Ken Mills, announced last year, where we target having 5 programs, either our own or licensed programs advance to pivotal or commercial stage by 2025.

And we as a leading AAV gene therapy company, from a scientific standpoint, clinical development standpoint and also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot